Janssen Receives Positive CHMP Opinion for IMBRUVICA (ibruti

The positive opinion is based on Phase 3 GLOW and Phase 2 CAPTIVATE study results, which investigated the efficacy and safety of ibrutinib plus venetoclax in patients with previously untreated CLL1

Related Keywords

United States , American , Craig Tendler , Jenni Mildon , Edmond Chan , Hematology Am Soc Hematol Educ Program , Janssen Biotech Inc , European Hematology Association , Janssen Research Development , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , American Society Of Hematology , American Society Of Clinical Oncology Annual Meeting , Diagnostics Medical Affairs , Committee For Medicinal Products Human Use , Global Head Of Late Development , American Cancer Society , None Of The Janssen Pharmaceutical Companies , European Commission , World Health Organisation , Exchange Commission , Companies Of Johnson , European Medicines Agency , Johnson , Medicinal Products , Human Use , Area Lead Haematology , American Society , Global Head , Slate Development , Hematology Oncology , Janssen Biotech , World Health Organization , Model Lists , Essential Medicines , Product Characteristics , Chronic Lymphocytic Leukaemia , Pharmaceutical Companies , Metabolism Retina , Infectious Diseases Vaccines , Janssen Cilag Limited , Concerning Forward Looking Statements , Private Securities Litigation Reform Act , Janssen Pharmaceutica , Annual Report , Note Regarding Forward Looking , Quarterly Reports , Duration Ibrutinib Venetoclax , Chronic Lymphocytic Leukemia , First Line Treatment , Plus Venetoclax , For Chronic Lymphocytic Leukemia , Small Lymphocytic Lymphoma , Primary Analysis , Clinical Oncology Annual , Phasei Dose Escalation Study , Btk Inhibitor , Refractoryb Cell Non Hodgkin Lymphoma , Novel Fluorescent Probe Pharmacodynamic , Practice Guidelines , Treatment Options , Janssen , Eceives , Positive , Thmp , Opinion , Imbruvica , Ibrutinib , Ixed , Uration , Combination , Regimen , Adult , Patients , Reviously , Untreated , Hronic , Lymphocytic , Leukaemia ,